Invention Grant
- Patent Title: Rapamycin-resistant T cells and therapeutic uses thereof
- Patent Title (中): 雷帕霉素抗性T细胞及其治疗用途
-
Application No.: US11298313Application Date: 2005-12-09
-
Publication No.: US07718196B2Publication Date: 2010-05-18
- Inventor: Daniel H. Fowler , Unsu Jung , Ronald E. Gress , Bruce Levine , Carl June
- Applicant: Daniel H. Fowler , Unsu Jung , Ronald E. Gress , Bruce Levine , Carl June
- Applicant Address: US DC Washington US PA Philadelphia
- Assignee: The United States of America, as represented by the Department of Health and Human Services,The Trustees of the University of Pennsylvania
- Current Assignee: The United States of America, as represented by the Department of Health and Human Services,The Trustees of the University of Pennsylvania
- Current Assignee Address: US DC Washington US PA Philadelphia
- Agency: Edwards Angell Palmer & Dodge LLP
- Agent Peter F. Corless; Christine C. O'Day
- Main IPC: A61K35/28
- IPC: A61K35/28 ; C12N5/08

Abstract:
Methods for generating highly enriched Th1/Tc1 and Th2/Tc2 functions are described. In particular, the generation of these functions are attained by the addition of an immune suppression drug, rapamycin or a rapamycin derivative compound. In addition to enhanced purity of T cell function, the T cells generated in rapamycin also express molecules that improve immune T cell function such as CD28 and CD62L. Such rapamycin generated functional T cell subsets may have application in the prevention or treatment of GVHD after allogeneic hematopoietic stem cell transplantation, the treatment of autoimmunity, or the therapy of infection or cancer.
Public/Granted literature
- US20060159667A1 Rapamycin-resistant T cells and therapeutic uses thereof Public/Granted day:2006-07-20
Information query
IPC分类: